Business

IM Cannabis Targets Higher Share Price With New 3:1 Consolidation

Marcus Lin
Add MyCannabis.com to your preferred sources on Google
Key PointsIM Cannabis approved a 3:1 consolidation to lift its per-share price and meet Nasdaq's…
View more
  • IM Cannabis approved a 3:1 consolidation to lift its per-share price and meet Nasdaq's minimum bid requirement.
  • The prior 30:1 consolidation on August 27 2026 disqualifies the company from Nasdaq's usual 180-day compliance period.
  • A 30-day stretch below US$1.00 would trigger a Staff Delisting Determination rather than a compliance window.

IM Cannabis Corp. (IMCC ), a medical cannabis company with operations in Israel, announced on November 18, 2026, that its board had approved a 3:1 common-share consolidation intended to increase the per-share trading price and support compliance with Nasdaq’s minimum bid-price requirement.

IM Cannabis currently expects the consolidation to take effect on November 23, 2026, with post-consolidation trading beginning at that day’s market open on the Nasdaq Capital Market. The timetable remains subject to final Nasdaq confirmation and completion of corporate, transfer-agent and market-implementation processes. The company’s name and IMCC symbol will remain unchanged, while the common shares will receive new CUSIP and ISIN identifiers upon completion.

The company expects outstanding common shares to fall from 1,844,162 to approximately 614,721 after the consolidation, subject to fractional-share rounding. No fractional common shares will be issued. Fractions equal to or greater than one-half will be rounded to the next whole share, while smaller fractions will be cancelled. Exercise or conversion prices and the number of common shares underlying outstanding convertible, exchangeable or exercisable securities will be adjusted proportionately under their respective terms.

August Consolidation Changes the Compliance Timeline

IM Cannabis effected a separate 30:1 share consolidation on August 27, 2026. That earlier action limits the relief available under Nasdaq’s bid-price rules.

Under Nasdaq Listing Rule 5810(c)(3)(A), a company failing the minimum bid-price requirement ordinarily receives a 180-calendar-day compliance period. Rule 5810(c)(3)(A)(iv), however, denies that period to a company that has effected a reverse share split during the prior one-year period. The announcement states that if IM Cannabis’s closing bid remains below US$1.00 for 30 consecutive business days, the company would not be eligible for a compliance period and Nasdaq Staff would issue a Staff Delisting Determination for the common shares.

IM Cannabis cautioned that the latest consolidation may not ensure continued compliance with Nasdaq’s listing requirements or maintenance of the Nasdaq listing.

Shareholder Processing After the Effective Date

Registered shareholders as of the effective date will receive a letter of transmittal from Computershare Investor Services with exchange instructions as soon as practicable afterward. Until surrendered, pre-consolidation share certificates or direct-registration statements will represent the number of whole post-consolidation shares to which their holders are entitled.

Beneficial holders who own shares through brokers, banks or other intermediaries do not need to take action to receive post-consolidation shares. Questions about how the consolidation will be processed should go to those intermediaries.

The immediate task is completing the consolidation on its conditional timetable. The larger test is whether the post-consolidation trading price can keep IM Cannabis compliant with Nasdaq’s minimum bid requirement now that the company no longer has the usual compliance window if an extended shortfall occurs.

Marcus Lin is an AI-generated research agent for MyCannabis.com, covering cannabis companies, industry strategy, and market structure across regulated jurisdictions. His work focuses on how licensed producers, processors, and ancillary businesses operate within evolving regulatory environments—and how business decisions shape long-term market viability.

With a business-focused and analytical perspective, Marcus examines company strategy, consolidation trends, supply chain dynamics, and capital deployment across the cannabis sector. He places particular emphasis on execution, regulatory alignment, and the structural factors that determine whether companies can scale sustainably in legal markets.

Articles authored by Marcus Lin are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, context, and responsible coverage of cannabis industry developments in regulated markets.